Hematological Neoplasms

On October 18, 2017, the U.S. FDA approved the CAR-T cell therapy Yescarta for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including patients with diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.

On May 27, 2022, Novartis announced on its official website that the U.S. FDA has granted accelerated approval for a new indication of its CAR-T cell therapy Kymriah (tisagenlecleucel) for the treatment of adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) after two or more lines of systemic therapy.

On May 2, 2018, the U.S. FDA approved Novartis’ CAR-T cell therapy drug Kymriah (Tisagenlecleucel, CTL019) for a second indication, to treat adult patients with relapsed or refractory large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy, including the most common form of non-Hodgkin lymphoma—diffuse large B-cell lymphoma (DLBCL)—as well as high-grade B-cell lymphoma and DLBCL arising from follicular lymphoma (FL).

Although autologous anti-CD19 CAR-T cell therapy is highly effective in treating large B-cell lymphomas, less than half of r/rDLBCL patients experience a response duration exceeding 1 year.

As an emerging cancer treatment, chimeric antigen receptor T-cell (CAR-T) therapy has achieved significant therapeutic effects in the treatment of lymphoma.

On February 8, 2023, JCO Online published the clinical results from the US Lymphoma CAR-T Alliance on Brexucabtagene Autoleucel (Tecartus, brexu-cel) as a standard treatment for relapsed/refractory mantle cell lymphoma. Let’s take a look with the editor.

Currently, CAR-T cell therapy is applicable to the treatment of B-NHL and relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) in children and adults.

Currently, there is no clearly defined standard of care (SOC) for patients with relapsed/refractory follicular lymphoma (R/R FL).

Kymriah (Tisagenlecleucel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy that has shown clinically meaningful results in patients with relapsed/refractory B-cell lymphoma.

On March 18, 2024, at Ruijin Hospital in Shanghai, China, the 100th patient with relapsed/refractory lymphoma achieved complete remission after CAR-T cell therapy and was discharged.

Promising News from Cellular Therapy. On March 29, 2024, Ms. Mo (alias), a patient with diffuse large B-cell lymphoma who received CAR-T cell therapy, was discharged from the Department of Hematology and Rheumatology at the People’s Hospital of Zhuhai.

Can a single injection eliminate cancer cells? If it weren’t for her own personal experience, Ms. Zhou, who had been tormented by relapsed/refractory diffuse large B-cell lymphoma (DLBCL) for a long time, would hardly believe it.